Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Sao Jiralerspong
Associate Professor, Medicine - (Clinical Scholar Track)
Medicine
Overview
Research
More
Collaboration
(15)
Mohab Ibrahim
Mutual work: 1 Publication
Collaboration Details
Denise Roe
Mutual work: 6 Publications
Collaboration Details
Todd Vanderah
Mutual work: 1 Publication
Collaboration Details
Jennifer Segar
Mutual work: 6 Grants﹒5 Publications﹒9 Proposals
Collaboration Details
Jennifer Erdrich
Mutual work: 2 Publications
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(6)
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for
Active
·
2024
·
$0 / $252.6K
·
External
Co-Investigator (COI)
breast cancer,
adjuvant therapy,
immunotherapy,
clinical trial,
hormone receptor
Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have R
Active
·
2023
·
$0 / $709.8K
·
External
Co-Investigator (COI)
breast cancer,
immunotherapy,
clinical trials,
combination therapy,
precision medicine
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of
Active
·
2023
·
$0 / $342.9K
·
External
Co-Investigator (COI)
cancer treatment,
drug combination,
efficacy,
safety
A Phase 1/2, Open Label, Dose-Escalation Study Of Oral ORIN1001 With And Without Chemotherapy In The Treatment Of Subjects With Solid Tumors
Active
·
2022
·
$0 / $245.9K
·
External
Co-Investigator (COI)
oncology,
clinical trial,
chemotherapy,
solid tumors,
dose escalation
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients with Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy
Active
·
2022
·
$0 / $185.5K
·
External
Co-Investigator (COI)
cancer immunotherapy,
metastatic breast cancer,
immunotherapy combinations,
hormone therapy resistance
Page 1 of 2
Previous page
Next page
Publications
(10)
Recent
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer
2021
cancer,
drug combination,
metformin,
insulin/igf-1 receptor,
breast cancer
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
2019
breast cancer,
neoadjuvant therapy,
her2 positive,
lapatinib,
trastuzumab
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia
2019
vitamin d supplementation,
arthralgia prevention,
randomized controlled trial,
aromatase inhibitor,
high-dose versus standard-dose
Unbiased Lipidomic Profiling of Triple-Negative Breast Cancer Tissues Reveals the Association of Sphingomyelin Levels with Patient Disease-Free Survival
2018
lipidomics,
breast cancer,
tissue profiling,
sphingomyelin,
patient survival
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
2016
obesity,
breast cancer,
prognosis,
evidence,
challenges
Metformin in breast cancer an evolving mystery
2015
metformin,
breast cancer,
treatment,
mystery,
evolving
Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients
2013
obesity,
diabetes,
breast cancer,
survival outcomes
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer
2009
Encounter and extrusion of an intrahelical lesion by a DNA repair enzyme
2009
Expanding the arsenal: metformin for the treatment of triple-negative breast cancer?
2009